At 36x earnings with a Forward P/E of 23.2 and a PEG of 0.9, the market is clearly pricing in a sharp earnings reset while still assigning some growth optionality. A Price/Sales of 0.4 and Price/Book of 0.7 scream deep value, yet the underlying profitability profile—2.00% operating margin, -2.00% ROE, and 2.40% ROIC—justifies skepticism. The Altman Z-Score of 2.4 places the company in a grey zone where balance sheet risk is not trivial, especially with 4.40% Debt/Equity. This is not a pristine compounder mispriced by the market; it is a cyclical asset with compressed profitability where the valuation reflects both distress risk and potential normalization.